Refractory Gastroesophageal Junction Adenocarcinoma Clinical Trials in Chicago, Illinois

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors